The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by Citizens Capital Markets on February 28, 2025. The analyst firm set a price target for $87.00 expecting GPCR to rise to within 12 months (a possible 273.87% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Structure Therapeutics (NASDAQ:GPCR) was provided by Citizens Capital Markets, and Structure Therapeutics maintained their market outperform rating.

There is no last upgrade for Structure Therapeutics

There is no last downgrade for Structure Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Structure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Structure Therapeutics was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.

While ratings are subjective and will change, the latest Structure Therapeutics (GPCR) rating was a maintained with a price target of $91.00 to $87.00. The current price Structure Therapeutics (GPCR) is trading at is $23.27, which is out of the analyst’s predicted range.